reproductive medicine
FDA approves Ferring’s Adstiladrin as first gene therapy for bladder cancer
Non-muscle-invasive bladder cancer represents around 75% of all new bladder cancer cases
Ferring agrees Chinese reproductive medicine research deal
Work with the Chinese Academy of Sciences on the long-term project
NICE finally set to back wider use of Ferring’s Firmagon
And acknowledges drug's benefits for prostate cancer that spreads to the spine
Ferring signs telemedicine collaboration with Danish hospital
Will work with North Zealand University Hospital on IBD patient care
Ferring collaborates on novel IBD drug development
Project in partnership with Paris-based Institut Pasteur
Ferring’s Inna Demidova moves to ELC
Takes up Russia and CIS role at the regulatory affairs specialist
NICE gives partial backing to Ferring’s prostate cancer drug
Firmagon on course for use on NHS in England and Wales
Interview: Michel Pettigrew, Ferring
Ferring Pharmaceuticals' president on how the company encourages 'controlled entrepreneurship'
